Abstract
Endothelial progenitor cells (EPCs) correspond to a population of cells with novel properties capable of angiogenesis and vasculogenesis, thus they are likely to display unique role in the reconstitution of the blood brain barrier (BBB) after stroke. Laboratory evidence supports safety and efficacy of cell therapy for stroke, with limited clinical trials recently initiated. This lab-to-clinic ascent of cellbased therapeutics has been aided by the establishment of consortium consisting of thought-leaders from academia, industry, National Institutes of Health (NIH) and the United States Food and Drug Administration (FDA). However, there remain unanswered questions prior to realization of large-scale application of cell transplantation in patients. This review article discusses translational challenges associated in cell therapy, emphasizing the need for optimizing both safety and efficacy profiles for advancing the clinical applications of EPC transplantation for stroke patients.
Keywords: Cerebral ischemia, stem cells, cell transplantation, translational research, Endothelial progenitor cells (EPCs), blood brain barrier (BBB), stroke, cell therapy, Hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs).
Current Pharmaceutical Design
Title:Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells
Volume: 18 Issue: 25
Author(s): Yuji Kaneko, Naoki Tajiri, Kazutaka Shinozuka, Loren E. Glover, Nathan L. Weinbren, Lourdes Cortes and Cesar V. Borlongan
Affiliation:
Keywords: Cerebral ischemia, stem cells, cell transplantation, translational research, Endothelial progenitor cells (EPCs), blood brain barrier (BBB), stroke, cell therapy, Hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs).
Abstract: Endothelial progenitor cells (EPCs) correspond to a population of cells with novel properties capable of angiogenesis and vasculogenesis, thus they are likely to display unique role in the reconstitution of the blood brain barrier (BBB) after stroke. Laboratory evidence supports safety and efficacy of cell therapy for stroke, with limited clinical trials recently initiated. This lab-to-clinic ascent of cellbased therapeutics has been aided by the establishment of consortium consisting of thought-leaders from academia, industry, National Institutes of Health (NIH) and the United States Food and Drug Administration (FDA). However, there remain unanswered questions prior to realization of large-scale application of cell transplantation in patients. This review article discusses translational challenges associated in cell therapy, emphasizing the need for optimizing both safety and efficacy profiles for advancing the clinical applications of EPC transplantation for stroke patients.
Export Options
About this article
Cite this article as:
Kaneko Yuji, Tajiri Naoki, Shinozuka Kazutaka, E. Glover Loren, L. Weinbren Nathan, Cortes Lourdes and V. Borlongan Cesar, Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002733
DOI https://dx.doi.org/10.2174/138161212802002733 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fullerenes for Applications in Biology and Medicine
Current Medicinal Chemistry Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry The Antiplatelet and Antithrombotic Actions of Statins
Current Pharmaceutical Design The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 6
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Strict Adherence to Guidelines in Decision Making for Coronary Angiography in Patients Who have Survived a Q Wave Myocardial Infarction; 2-Year Outcome in a Greek Population
Vascular Disease Prevention (Discontinued) Nitric Oxide and Cardiovascular Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Insights Into Early and Rapid Effects of Statin Therapy after Coronary Interventions
Current Pharmaceutical Design Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) The Innate Immune System and Fever under Redox Control: A Narrative Review
Current Medicinal Chemistry Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design New Horizons in Diabetes Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews Gender and Cardiovascular Mortality in Northern and Southern European Populations
Current Pharmaceutical Design Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Current Vascular Pharmacology Biomarkers in Unstable Carotid Plaque: Physiopathology and Prediction
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Current Diabetes Reviews